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valves. However, whether zinc directly regulates calcific aortic valve disease is yet to
be elucidated. The present study sought to determine the potential role of zinc in the
pathogenesis of calcific aortic valve disease.
Methods and Results:  Using a combination of a human valve interstitial cell
calcification model, human aortic valve tissues and blood samples, we report that 20
μM zinc supplementation attenuates human valve interstitial cell (hVIC)  in vitro
calcification, and that this is mediated through inhibition of apoptosis and osteogenic
differentiation via the zinc sensing receptor GPR39-dependent ERK1/2 signaling
pathway. Furthermore, we report that GPR39 protein expression is dramatically
reduced in calcified human aortic valves, and there is a significant reduction in zinc
serum levels in patients with calcific aortic valve disease. Moreover, we reveal that 20
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μM zinc treatment prevents the reduction of GPR39 observed in calcified human valve
interstitial cells. We also show that the zinc transporter ZIP13 and ZIP14 are
significantly increased in hVICs in response to zinc treatment. Knockdown of ZIP13 or
ZIP14 significantly inhibited hVIC  in vitro  calcification and osteogenic differentiation.
Conclusions:  Together, these findings suggest that zinc is a novel inhibitor of calcific
aortic valve disease, and report that zinc transporter ZIP13 and ZIP14 are important
regulators of hVIC  in vitro  calcification and osteogenic differentiation. Zinc
supplementation may offer a potential therapeutic strategy for calcific aortic valve
disease. 
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vitro  calcification through inhibition of apoptosis and osteogenic differentiation via
GPR39-dependent ERK1/2 signaling pathway. Zinc transporter ZIP13 and ZIP14 are
important regulators of hVIC  in vitro  calcification and osteogenic differentiation. Zinc
supplementation is a potential therapeutic strategy for calcific aortic valve disease.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Abstract  
 
Aims: Calcific aortic valve disease is the most common heart valve disease in the 
Western world. It has been reported that zinc is accumulated in calcified human aortic 
valves. However, whether zinc directly regulates calcific aortic valve disease is yet to 
be elucidated. The present study sought to determine the potential role of zinc in the 
pathogenesis of calcific aortic valve disease. 
 
Methods and Results: Using a combination of a human valve interstitial cell 
calcification model, human aortic valve tissues and blood samples, we report that 20 
μM zinc supplementation attenuates human valve interstitial cell (hVIC) in vitro 
calcification, and that this is mediated through inhibition of apoptosis and osteogenic 
differentiation via the zinc sensing receptor GPR39-dependent ERK1/2 signaling 
pathway. Furthermore, we report that GPR39 protein expression is dramatically 
reduced in calcified human aortic valves, and there is a significant reduction in zinc 
serum levels in patients with calcific aortic valve disease. Moreover, we reveal that 20 
μM zinc treatment prevents the reduction of GPR39 observed in calcified human 
valve interstitial cells. We also show that the zinc transporter ZIP13 and ZIP14 are 
significantly increased in hVICs in response to zinc treatment. Knockdown of ZIP13 
or ZIP14 significantly inhibited hVIC in vitro calcification and osteogenic 
differentiation.  
 
Conclusions: Together, these findings suggest that zinc is a novel inhibitor of calcific 
aortic valve disease, and report that zinc transporter ZIP13 and ZIP14 are important 
regulators of hVIC in vitro calcification and osteogenic differentiation. Zinc 
supplementation may offer a potential therapeutic strategy for calcific aortic valve 
disease.   
  
Translational Perspective 
This study reports that the zinc sensing receptor GPR39 expression is decreased in 
calcified human aortic valve tissues and there is a significant reduction in zinc serum 
levels in patients with calcific aortic valve disease. Zinc treatment attenuates hVIC in 
vitro calcification through inhibition of apoptosis and osteogenic differentiation via 
GPR39-dependent ERK1/2 signaling pathway. Zinc transporter ZIP13 and ZIP14 are 
important regulators of hVIC in vitro calcification and osteogenic differentiation. Zinc 
supplementation is a potential therapeutic strategy for calcific aortic valve disease.   
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Abstract  1 
 2 
Aims: Calcific aortic valve disease is the most common heart valve disease in the Western 3 
world. It has been reported that zinc is accumulated in calcified human aortic valves. However, 4 
whether zinc directly regulates calcific aortic valve disease is yet to be elucidated. The present 5 
study sought to determine the potential role of zinc in the pathogenesis of calcific aortic valve 6 
disease. 7 
 8 
Methods and Results: Using a combination of a human valve interstitial cell calcification 9 
model, human aortic valve tissues and blood samples, we report that 20 μM zinc 10 
supplementation attenuates human valve interstitial cell (hVIC) in vitro calcification, and that 11 
this is mediated through inhibition of apoptosis and osteogenic differentiation via the zinc 12 
sensing receptor GPR39-dependent ERK1/2 signaling pathway. Furthermore, we report that 13 
GPR39 protein expression is dramatically reduced in calcified human aortic valves, and there 14 
is a significant reduction in zinc serum levels in patients with calcific aortic valve disease. 15 
Moreover, we reveal that 20 μM zinc treatment prevents the reduction of GPR39 observed in 16 
calcified human valve interstitial cells. We also show that the zinc transporter ZIP13 and 17 
ZIP14 are significantly increased in hVICs in response to zinc treatment. Knockdown of 18 
ZIP13 or ZIP14 significantly inhibited hVIC in vitro calcification and osteogenic 19 
differentiation.  20 
 21 
Conclusions: Together, these findings suggest that zinc is a novel inhibitor of calcific aortic 22 
valve disease, and report that zinc transporter ZIP13 and ZIP14 are important regulators of 23 
hVIC in vitro calcification and osteogenic differentiation. Zinc supplementation may offer a 24 
potential therapeutic strategy for calcific aortic valve disease.   25 
  26 
Translational Perspective 27 
This study reports that the zinc sensing receptor GPR39 expression is decreased in calcified 28 
human aortic valve tissues and there is a significant reduction in zinc serum levels in patients 29 
with calcific aortic valve disease. Zinc treatment attenuates hVIC in vitro calcification 30 
through inhibition of apoptosis and osteogenic differentiation via GPR39-dependent ERK1/2 31 
signaling pathway. Zinc transporter ZIP13 and ZIP14 are important regulators of hVIC in 32 
vitro calcification and osteogenic differentiation. Zinc supplementation is a potential 33 
therapeutic strategy for calcific aortic valve disease.   34 
 35 
 36 











1. Introduction 45 
 46 
Calcific aortic valve disease (CAVD), the most common heart valve disease, is a major 47 
public health problem in the Western world. It is a chronic disorder that is characterized by 48 
progressive fibrocalcific valve thickening and ventricular function impairment, subsequently 49 
leading to left ventricular outflow obstruction1. Traditional cardiovascular drugs such as 50 
statins are unable to prevent the progression of CAVD. Currently, the viable treatments for 51 
patients with severe CAVD are surgical valve replacement or transcatheter aortic valve 52 
implantation with the prosthetic valves2. However, these treatments are invasive, costly and 53 
risky for elderly adults, and it may lead to more severe complications including blood clots, 54 
infections, and heart attack. In addition, the prosthetic valves have limited durability, and 55 
undergo structural degeneration and calcification3. A better understanding of the 56 
pathophysiology of CAVD is therefore critical for the development of novel therapeutic 57 
strategies to slow or reverse the progression of CAVD. 58 
 59 
Accumulating evidence indicates that CAVD is an actively regulated and progressive 60 
disease, which shares many similarities to physiological bone mineralization. Osteogenic 61 
genes like runt-related transcription factor 2 (RUNX2) have been shown to be up-regulated in 62 
calcified human aortic valves4. Patients with chronic kidney disease (CKD) have increased 63 
circulating calcium (Ca) and phosphate (Pi) levels, and are highly susceptible to CAVD5, 6.  64 
Accordingly, we and others have previously reported that valve interstitial cells (VICs), the 65 
most abundant cell type in the aortic valve, undergo osteogenic differentiation in response to 66 
high Ca and Pi mimicking that observed in CKD patients7, 8. Based on these observations, it is 67 
now recognized that the osteogenic differentiation of VICs plays an important role in the 68 
development of CAVD. Furthermore, cytokines involved in calcification including the 69 
transforming growth factor-β1 (TGFβ1) and TNF-related apoptosis-inducing ligand (TRAIL) 70 
are overexpressed in calcific aortic valves9, 10. These cytokines promote aortic valve 71 
calcification through induction of VIC apoptosis9, 10. Conversely, pro-survival signals like 72 
ATP have been shown to prevent aortic valve calcification11. These studies suggest that 73 
apoptosis is also involved in the pathogenesis of CAVD. 74 
 75 
Zinc is an important micronutrient for health, which modulates numerous cellular 76 
processes including DNA and protein synthesis, enzyme activity, and intracellular signaling. 77 
Zinc deficiency is associated with cardiovascular disease. It has been shown that zinc 78 
deficiency enhances vascular inflammation and atherosclerotic plaque formation in ApoE 79 
knockout mice12. Accordingly, zinc supplementation attenuates a high cholesterol 80 
diet-induced atherosclerosis in rabbits13. Zinc has also been reported to inhibit abdominal 81 
aortic aneurysm formation in mice through induction of zinc finger protein A20-mediated 82 
suppression of nuclear factor κB (NF-κB) pathway14. Furthermore, a recent study has 83 
demonstrated that zinc ameliorates phosphate-induced osteogenic transition of vascular 84 
smooth muscle cells (VSMCs) and vascular calcification through the G protein coupled 85 
receptor 39 (GPR39)-dependent induction of TNF-α–induced protein 3 (TNFAIP3) and 86 
subsequent suppression of the NF-kB pathway15. Interestingly, zinc has been shown to be 87 




of CAVD has not been previously investigated.  89 
 90 
In the present study, we have performed detailed analysis of clinical samples from 91 
patients with CAVD in conjunction with in vitro calcification studies in hVICs to address the 92 
possible effects of zinc and zinc transporters on aortic valve calcification and the underlying 93 
mechanisms through which zinc and zinc transporters may regulate CAVD.    94 
 95 
2. Experimental procedures 96 
 97 
2.1 Human samples 98 
This study complies with the Declaration of Helsinki and approved by The Research 99 
Ethics Committee of Guangdong Provincial People’s Hospital and Guangzhou Medical 100 
University (Ref No: GDREC2019433H). 34 tricuspid aortic valves from patients with CAVD 101 
(25 males/9 females) and 4 non-calcified aortic valves from patients with aortic valve 102 
prolapse (4 males) undergoing valve replacement surgery were collected at Guangdong 103 
Provincial People’s Hospital (Guangzhou, China). Marked increase in echogenicity of aortic 104 
valves measured by echocardiograms was considered as CAVD by clinical doctors. A 105 
representative still image of echocardiograms of a patient with CAVD is shown in 106 
Supplementary Figure I. Patients with a history of rheumatic disease, congenital valve disease, 107 
and infective endocarditis were excluded. Human blood samples were also collected from 15 108 
healthy volunteers and 15 patients with CAVD at Guangdong Provincial People’s Hospital 109 
(Guangzhou, China). Informed consent was obtained from all patients. Serum was obtained 110 
by immediate centrifugation and stored at -80°C. Clinical characteristics of the patients used 111 
in the present study are summarized in Supplementary material Table I-III. The methodology, 112 
conduct, and reporting of this study were in accordance with the Strengthening the Reporting 113 
of Observational Studies in Epidemiology (STROBE) Statement initiatives for case-control 114 
studies17. STROBE recommendations for reporting case-control studies are available as 115 
Supplementary material Table IV.  116 
 117 
2.2 Measurement of zinc serum levels 118 
Zinc concentrations were analyzed by an automatic biochemical analyzer (Chemray 240) 119 
with the Zinc Assay Kit (Changchun Huili Biotech, C017) according to the manufacturer’s 120 
instructions.  121 
 122 
2.3 Isolation of Human Valve Interstitial Cells (hVICs) 123 
hVICs were isolated from non-calcified areas of the valves from patients with CAVD, 124 
and the purity of cell preparation was characterized as previously described8. Briefly, 125 
non-calcified areas of valve leaflets were dissected, incubated with 1 mg/ml trypsin (Gibco, 126 
12605-010) for 10 min and washed in HBSS buffer (Hyclone, SC30588.01) to remove valve 127 
endothelial cells. The valve tissues were then digested in 250 U/ml type II collagenase 128 
solution (Worthington, 47D17411A) at 37°C for 7 hrs. The cells subsequently obtained were 129 
re-suspended in growth media consisting of α-MEM supplemented with 10% FBS (Gibco, 130 
16000-044), 100 U/mL of penicillin (HyClone, SH40003.01), and 100 mg/ml of streptomycin 131 




(Gibco, A1048301). Cells used for experiments in the present study were between 2-4 133 
passages.  134 
 135 
2.4 Induction of hVIC in vitro calcification  136 
hVICs were seeded at the density of 1.0x105 cells/well in 6-well plates and cultured with 137 
growth media. Calcification was induced as previously described8. Briefly, hVICs were 138 
grown to confluence and treated with control (1.0 mM Pi/1.8mM Ca) or calcifying media (50 139 
µg/mL ascorbic acid/2.5 mM Pi/2.7 mM Ca) for up to 7 days. Pi was prepared as a 140 
combination of NaH2PO4/Na2HPO4, pH=7.4. To evaluate the effects of zinc on hVIC in vitro 141 
calcification, the indicated concentrations (0-20 μM) of ZnSO4 (Sigma, Z2051), the specific 142 
zinc chelator N,N,N’,N’-tetrakis (2-pyridinylmethyl)-1,2-ethanediamine (TPEN) (Sigma, 143 
P4431), ZnCl2 (Sigma, 746355), albumin (Sigma, SRP6516) and ERK1/2 inhibitor PD98059 144 
(Cell Signaling Technology, 9900) were added to the culture media. The media was changed 145 
every third/fourth day.  146 
 147 
2.5 Determination of hVIC in vitro calcification  148 
Calcium deposition was determined by alizarin red staining and calcium colorimetric 149 
assay. Briefly, the cells were washed twice with cold PBS, fixed with 4% paraformaldehyde 150 
(PFA) for 10 min, stained with 2% alizarin red (pH 4.2) for 10 min at room temperature, and 151 
photographed. The cells were also decalcified with 0.6 M HCl at 4oC overnight. Free calcium 152 
in the supernatants was determined using a calcium colorimetric assay (Sigma, MAK022-1KT) 153 
according to the manufacturer’s instructions. Cells were washed with PBS twice and 154 
harvested in lysis buffer (1 mM NaOH/0.1% SDS) for protein extraction. The total protein 155 
concentration was determined with bicinchoninic acid (BCA) protein assay kit (Thermo 156 
Fisher, 23235). Calcium content was normalized to total cell protein and expressed as μg/mg 157 
protein. 158 
 159 
2.6 Intracellular zinc detection 160 
hVICs were cultured with control or calcifying media in the presence of 20 μM ZnSO4 161 
and/or 20μM TPEN for up to 7 days. Intracellular zinc was detected using the zinc-selective 162 
indicator FluoZin-3 AM (Invitrogen, F24195) following the manufacturer’s instructions. 163 
Briefly, cells were incubated with 1 μM of FluoZin-3 AM containing 0.02% Pluronic F-127 164 
(Invitrogen, F24195) for 30 min at 37oC. After washing with Ca2+ and Mg2+ free PBS, cells 165 
were incubated for an additional 30 min at 37oC, and mounted in warm PBS buffer containing 166 
DAPI. Fluorescence images were detected by excitation at 488 nm and emission at 542 nm 167 
under a Leica DMRB fluorescence microscope (Leica SP8). 168 
 169 
2.7 Immunofluorescence staining  170 
To evaluate the expression of GPR39, hVICs were cultured with control or calcifying 171 
media in the presence or absence of 20 μM ZnSO4 for up to 7 days. Cells were fixed, 172 
permeabilized with 0.3% triton x-100 (Beyotime Biotechnology, P0013B) and incubated 173 
overnight at 4°C with anti-GPR39 (1:500, Abcam, ab229648). After washing with PBS, cells 174 
were incubated with Alexa Fluor®488 anti-rabbit antibodies (1:1000, Invitrogen, A11008) in 175 




and fluorescence signal was detected under Leica DMRB fluorescence microscope (Leica 177 
SP8). Negative controls were carried out simultaneously by incubating with equivalent 178 
concentrations of normal rabbit IgG (Santa Cruz, sc2025) instead of primary antibody. 179 
 180 
2.8 Quantitative RT-PCR  181 
Total RNA was extracted from hVICs using TaKaRa MiniBEST Universal RNA 182 
Extraction Kit (Takara, 9767) and from human aortic valves using Trizol (Invitrogen, 183 
1596026) according to the manufacturers’ instructions. RNA was quantified and reverse 184 
transcribed using PrimeScript™ RT Master Mix (Takara, RR036A). Quantitative RT-PCR was 185 
performed with SYBR Premix Ex Taq II (Takara, RR820A) in the QuantStudio 5 real-time 186 
system (Life technologies). Each PCR was run in triplicate. All gene expression data were 187 
calculated using the 2− ΔΔCT method and normalized against GAPDH. The control values were 188 
expressed as 1 to indicate a precise fold change value for each gene of interest. The primer 189 
sequences for target genes are summarized in Supplementary material Table V. 190 
 191 
2.9 Transfection of siRNAs 192 
hVICs were seeded at the density of 1.0x105 cells/well in 6-well plates and transfected 193 
with 25 nM GPR39 siRNA (RIBOBIO), ZIP13 siRNA (RIBOBIO), ZIP14 siRNA 194 
(RIBOBIO), ERK1/2 siRNA (RIBOBIO) or Non-targeting (siNC) siRNA (RIBOBIO) using 195 
Lipofectamine RNAiMAX (Invitrogen, 13778) following the manufacturer’s instructions. The 196 
knockdown efficiency of siRNAs used in the present study was confirmed by quantitative 197 
RT-PCR and western blotting. For long-term hVIC in vitro calcification, cells were 198 
re-transfected at day 3 and incubated with calcifying media for up to 7 days. The siRNA 199 
sequences for gene silencing are summarized in Supplementary material Table VI. 200 
  201 
2.10 Western blotting  202 
hVICs were harvested with RIPA lysis buffer (Beyotime Biotechnology, P0013B) 203 
containing 1 mM protease inhibitor phenylmethylsulfonyl fluoride (PMSF) (Beyotime 204 
Biotechnology, ST505). Western blotting was performed. Equal amounts of protein lysates 205 
were separated on SDS-Polyacrylamide gels and transferred to PVDF membranes. The 206 
membranes were incubated overnight at 4 °C with primary antibodies: anti-caspase 3 (1:2000, 207 
Cell Signaling Technology, 9662S), anti-cleaved caspase 3 (1:2000, Cell Signaling 208 
Technology, 9664S), anti-pAKT (1:4000, Cell Signaling, 4060S), anti-AKT (1:4000, Cell 209 
Signaling Technology, 9272), anti-pERK (1:4000, Cell Signaling Technology, 9101), 210 
anti-ERK (1:4000, Cell Signaling Technology, 4695), Anti-GPR39 (1:2000, Abcam, 211 
ab229648), Anti-RUNX2 (1:2000, Abcam, ab23981), Anti-MSX2 (1:2000, Santa Cruz, 212 
sc-393986), Anti-ZIP13 (1:2000, Abcam, ab106586), Anti-ZIP14 (1:2000, Abcam, ab106568), 213 
anti-β-actin (1:2000, Santa Cruz, J1116). Subsequently, membranes were incubated with 214 
HRP-conjugated anti-mouse (1:4000, Cell Signaling Technology, 7076S) or anti-rabbit 215 
(1:4000, Cell Signaling Technology, 7074S) secondary antibodies for 1 hr at room 216 
temperature. The immune complexes were visualized by chemiluminescence Lumi-Light 217 
Western Blotting Substrate (Millipore, WBKLS0500). Semi-quantitative assessment of band 218 





2.11 Cell death assay 221 
hVICs were seeded at a density of 1.0x104/wells in 96-well plates and incubated with 222 
control or calcifying media in the presence or absence of 20 μM ZnSO4 for up to 7 days. Cell 223 
death was measured using Cytotoxicity lactic dehydrogenase (LDH) Assay Kit (Beyotime 224 
Biotechnology, C0038) following the manufacturer’s instructions. 225 
 226 
2.12 Calcium phosphate precipitation assay 227 
Calcium phosphate precipitation assay was performed as previously described15. Briefly, 228 
the indicated concentrations of ZnSO4 (0-20μM) was incubated with a homogeneous system 229 
containing 10 mM CaCl2 (Sigma, 793639) and 10 mM sodium phosphate buffer (pH7.4, 230 
Sigma, 342483) in 500 mM HEPES buffer (pH7.4, Sigma, RDD002) for 10 min at room 231 
temperature. The samples were then centrifuged at 1890g for 30 sec and the obtained pellet 232 
was dissolved in 0.6 M HCl. Calcium content in the pellet was determined using a calcium 233 
colorimetric assay (Sigma, MAK022-1KT). 234 
 235 
2.13 Apoptosis assay 236 
Apoptotic hVICs were determined by manually counting pyknotic nuclei after staining 237 
with DAPI (Cell Signaling, 4083S). In addition, hVICs in different stages of apoptosis were 238 
analyzed by flow cytometry using Dead Cell Apoptosis Kit with Annexin V Alexa Fluor™ 239 
488 & Propidium Iodide (PI) (Invitrogen, V13241) according to the manufacturer's 240 
instructions. In brief, hVICs were cultured with control or calcifying media in the presence or 241 
absence of 20 μM ZnSO4 for 3 days. Cells were harvested by trypsinization, washed with cold 242 
PBS and stained with Annexin V Alexa Fluor™ 488 and PI. 30,000 cell events were recorded 243 
on a BD FACS Calibur (Becton, Dickinson & Company) and data were analyzed with FlowJo 244 
8.8.4 flow cytometry analysis software (Tree Star Inc.). 245 
 246 
2.14 Histology and immunohistochemistry 247 
Human aortic valves tissues were fixed with 4% PFA for 24 hrs, dehydrated and 248 
embedded in paraffin wax before sectioning at 7 μm using standard procedures. For 249 
evaluation of calcium deposition, sections were de-waxed in xylene and stained with 2% 250 
Alizarin Red S solution for 5 min. After removal of the excess dye, sections were rinsed in 251 
100% acetone and %50:%50 acetone-xylene. Sections were then cleared in 100% xylene for 5 252 
min and mounted using neutral balsam (Solarbio, G8590). Light microscopy images were 253 
obtained by a scanning light microscope (Leica CS2). 254 
 255 
For immunohistochemistry, sections were subjected to sodium citrate (pH 6.0) for 256 
antigen retrieval for 10 min at 95 °C. Endogenous peroxidase activity and non-specific 257 
antibody binding were blocked before overnight incubation at 4 °C with anti-GPR39 antibody 258 
(1:500, Abcam, ab229648). The sections were then washed in PBS, and incubated with 259 
secondary antibody using ChemMateTM EnVisionTM Detection Kit (Gene Tech, GK500710) 260 
following the manufacturer’s instructions. The sections were finally counterstained with 261 
haematoxylin and eosin, dehydrated, and mounted in neutral balsam (Solarbio, G8590). 262 
Control sections were incubated with equal concentrations of normal rabbit IgG (Santa Cruz, 263 




scanner (Leica Aperio CS2). 265 
 266 
2.15 Statistical analysis 267 
All experiments were repeated at least 3 times and the representative results are shown. 268 
All values are expressed as mean ±SEM. Statistical analysis was performed using GraphPad 269 
Prism 6 (La Jolla, CA) software. After confirming a normal distribution using the 270 
Shapiro-Wilk test, data were analysed using unpaired Student’s t-test for comparison of two 271 
groups, one-way analysis of variance followed by Bonferroni post-test for comparison of 272 
multiple groups or a suitable non-parametric test such as Mann–Whitney. P< 0.05 was 273 
considered to be statistically significant.  274 
 275 
3. Results 276 
 277 
3.1 Zinc supplementation inhibits hVIC in vitro calcification and osteogenic 278 
differentiation 279 
Initial studies were performed to validate the hVIC in vitro calcification model. In 280 
accordance with our previous report8, hVICs showed positive staining for both SM22-α and 281 
Vimentin (Supplementary Figure II A). As revealed by alizarin red staining and quantitative 282 
calcium analysis, hVICs cultured under calcifying media showed significantly increased 283 
calcium deposition (12.15 fold, p<0.001; Supplementary Figure II B and C) at day 7. The 284 
osteogenic related genes including alkaline phosphatase (ALPL) (3.8 fold, p<0.001), Msh 285 
Homeobox 2 (MSX2) (3.9 fold, p<0.01), and RUNX2 (1.6 fold, p<0.001) were dramatically 286 
up-regulated in calcified hVICs compared to non-calcified hVICs (Supplementary Figure II 287 
D). Furthermore, increased cell death (11.5% at Day7, p<0.001) and apoptosis (2.0 fold, 288 
p<0.05) were observed during the process of hVIC in vitro calcification (Supplementary 289 
Figure II E and F). These results are consistent with previous reports4, 8.  290 
 291 
To evaluate the possible effects of zinc on hVIC in vitro calcification, hVICs were 292 
treated with 5-20 μM ZnSO4 in the presence of calcifying media for up to 7 days. Alizarin red 293 
staining and quantitative calcium analysis showed that 20μM ZnSO4 significantly attenuated 294 
calcium deposition in hVICs at day 7 (53% decrease, p<0.001; Figure 1A and 1B). To 295 
determine whether the inhibitory effect of ZnSO4 on hVICs in vitro calcification was 296 
specifically due to zinc ions, a specific zinc chelator TPEN was used. FluoZin-3 (a 297 
zinc-selective indicator) staining revealed that 20 μM TPEN dramatically abolished zinc 298 
accumulation in hVICs treated with 20 μM ZnSO4 at day 3 and day 7 (Figure 1C). As 299 
expected, 20 μM TPEN significantly blunted the inhibitory effect of 20 μM ZnSO4 on hVIC in 300 
vitro calcification (p<0.001; Figure 1D). Furthermore, ZnCl2 treatment also significantly 301 
inhibited calcium deposition in hVICs at day 7 (39% decrease, p<0.001; Figure 1E). 302 
Considering the important role of osteogenic differentiation of hVICs in aortic valve 303 
calcification4, 8, we next assessed whether zinc supplementation could reduce osteogenic 304 
related gene expression in hVICs. The up-regulation of ALPL and MSX2 in hVICs induced by 305 
calcifying media was significantly attenuated by zinc treatment after 7 days (Figure 1F and 306 
1G). It has been reported that serum albumin is the major zinc carrier in blood and responsible 307 




effect of zinc on hVIC calcification (Figure 1H). Taken together, these data suggest that zinc 309 
supplementation specifically inhibits hVIC in vitro calcification. 310 
 311 
3.2 Zinc prevents apoptosis during hVIC in vitro calcification 312 
Apoptosis has been previously reported to play a crucial role in initiation and 313 
progression of aortic valve calcification9-11, we therefore undertook a detailed assessment of 314 
apoptosis in hVICs following zinc treatment. 20 μM ZnSO4 treatment significantly reduced 315 
cell death (p<0.05; Figure 2A), apoptotic nuclei (p<0.001; Figure 2B) and apoptosis (50% 316 
decrease, p<0.05; Figure 2C) in hVICs cultured with calcifying media. Western blotting also 317 
showed that zinc supplementation prevented up-regulation of cleaved caspase3 in hVICs 318 
cultured with calcifying media at day 7 (Figure 2D, p<0.05). Calcium phosphate precipitation 319 
was not affected by ZnSO4 treatment (Figure 2E). In addition, zinc supplementation did not 320 
alter calcium phosphate deposition on fixed hVICs (Supplementary Figure III A and B). These 321 
data suggest no direct physicochemical inhibition of calcium/phosphate deposition by ZnSO4. 322 
We further examined the expression of TNFα and TFGβ, which are the important cytokines 323 
that involved in calcification through regulation of apoptosis9, 10. Zinc supplementation 324 
significantly attenuated the up-regulation of TNFα mRNA expression during hVIC in vitro 325 
calcification (45.2% decrease, Figure 2F, p<0.01). However, TGFβ mRNA expression was not 326 
altered in hVICs cultured with calcifying media in the absence or presence of zinc 327 
supplementation (Figure 2G). Taken together, our data suggests that zinc supplementation 328 
reduces hVIC in vitro calcification at least in part through inhibition of apoptosis. 329 
 330 
3.3 Zinc inhibits hVIC in vitro calcification and apoptosis through activation of the 331 
ERK1/2 signaling pathway  332 
To elucidate the underlying mechanisms of the protective effect of zinc on hVIC 333 
calcification, we investigated the activation of AKT and EKR1/2, which have been previously 334 
reported as key regulators of hVIC calcification19, 20. 20 μM ZnSO4 treatment significantly 335 
induced phosphorylation of ERK1/2 after 10 min (p<0.01) and 30 min (p<0.01), but not after 336 
60 min, while AKT phosphorylation was not induced by addition of ZnSO4 (Figure 3A). 20 337 
μM ZnSO4 treatment effectively inhibited hVIC in vitro calcification, as determined by 338 
alizarin red staining (Figure 3B) and calcium quantitative analysis (p<0.001, Figure 3C). 339 
Accordingly, the inhibitory effect of ZnSO4 on hVIC calcification was significantly abolished 340 
in the presence of the ERK1/2 inhibitor PD98059 (p<0.01, Figure 3B and 3C). ERK1/2 341 
inhibitor PD98059 by itself had no effect on hVIC calcification (Supplementary Figure IV A 342 
and B). Moreover, the inhibition of ZnSO4 on cleaved caspase3 (as an indication of apoptosis) 343 
expression (p<0.01, Figure 3D) and cell death (p<0.01, Figure 3E) in hVICs was also 344 
prevented by PD98059. In addition, siRNA-mediated knockdown of ERK1/2 also blunted the 345 
inhibitory effect of zinc on hVIC in vitro calcification (p<0.05, Figure 3F). ERK1/2 siRNA 346 
knockdown efficiency was confirmed by quantitative RT-PCR and western blotting 347 
(Supplementary Figure V A-C). These data support that activation of the ERK1/2 signaling 348 
pathway plays a key role in mediating the protective effect of zinc on hVIC calcification and 349 
apoptosis. 350 
 351 




inhibit hVIC calcification  353 
The zinc-sensing receptor GPR39 plays a key role in mediating zinc intracellular 354 
signaling pathways21. Additional experiments were therefore performed to examine the role of 355 
GPR39 in zinc mediated inhibition of hVIC calcification. The expression of GPR39 was 356 
detected in hVICs isolated from 5 patients with CAVD (Figure 4A). The endogenous 357 
expression of GPR39 was suppressed by transfection of GPR39 siRNA. Western blotting 358 
analysis showed that GPR39 siRNA 2 resulted in a significant reduction of GPR39 protein 359 
expression (Figure 4B). As expected, silencing of GPR39 attenuated zinc induced 360 
phosphorylation of ERK1/2 (20% decrease, p<0.01; Figure 4C). In addition, silencing of 361 
GPR39 by itself did not alter hVIC in vitro calcification, but significantly blunted the 362 
inhibitory effect of zinc supplementation on hVIC in vitro calcification (p<0.05; Figure 4D 363 
and E). siRNA knockdown of GPR39 also attenuated the inhibitory effects of zinc on hVIC 364 
apoptosis (p<0.05; Figure 4F) and the osteogenic gene MSX2 (p<0.05; Figure 4G) and BMP2 365 
mRNA expression (p<0.001; Figure 4H). The inhibitory effect of zinc on RUNX2 mRNA 366 
expression was not significantly affected by knockdown of GPR39 (Figure 4I). Our data 367 
support a key role of GPR39 in mediating the anti-calcific effects of zinc supplementation on 368 
hVICs. 369 
 370 
3.5 Knockdown of ZIP13 or ZIP14 inhibits hVIC in vitro calcification 371 
The human zinc transporter ZIP family consisting of 14 members functions to increase 372 
the cytosolic zinc accumulation by transporting zinc into the cytosol from the extracellular 373 
space or from intracellular compartments22. Among the 14 members of ZIP family examined, 374 
only ZIP13 (5.0 fold, p<0.05) and ZIP14 (1.8 fold, p<0.05) mRNA expression were 375 
significantly induced in hVICs treated with 20 μM ZnSO4 (Figure 5A). We therefore 376 
undertook further analysis to investigate the functional role of ZIP13 and ZIP14 in hVIC 377 
calcification. Knockdown efficiency of ZIP13 and ZIP14 was confirmed by quantitative 378 
RT-PCR and western blotting (Supplementary Figure V D-I). Knockdown of ZIP13 resulted 379 
in a significant decrease of calcium deposition in hVICs (30% decrease, p<0.05, Figure 5B 380 
and 5C). This inhibitory effect was further exacerbated in the presence of 20 μM ZnSO4 (50% 381 
decrease, p<0.05, Figure 5B and 5C). Consistent with these data, knockdown of ZIP13 382 
significantly reduced mRNA expression of the osteogenic related gene MSX2 (51.1% decrease, 383 
p<0.001, Figure 5F) in hVICs cultured with calcifying media after 7 days. However, this 384 
inhibition was abolished by zinc supplementation (Figure 5F). Knockdown of ZIP13 also 385 
decreased the osteogenic gene ALPL mRNA expression in hVICs cultured with calcifying 386 
media in the absence (63.6% decrease, p<0.05, Figure 5G) or presence (70.8% decrease, 387 
p<0.05, Figure 5G) of 20 μM ZnSO4 after 7 days. Knockdown of ZIP14 attenuated hVIC in 388 
vitro calcification (19% decrease, p<0.05, Figure 5D and 5E), but the addition of zinc to the 389 
knockdown of ZIP14 did not provide further reduction of the calcification process in hVIC 390 
cultures (Figure 5E). In addition, knockdown of ZIP14 resulted in a significant reduction in 391 
MSX2 mRNA expression in hVICs cultured with calcifying media in the absence (51.1% 392 
decrease, p<0.001, Figure 5F) or presence (43.5% decrease, p<0.01, Figure 5F) of 20 μM 393 
ZnSO4 after 7 days. However, knockdown of ZIP14 did not alter ALPL mRNA expression in 394 
hVICs (Figure 5G). We did not see any significant difference in the expression of ZIP13 and 395 




and B). Additionally, we observed that either knockdown of ZIP13 or ZIP14 dramatically 397 
reduced the cytosolic zinc concentrations in hVICs in the absence or presence of zinc 398 
supplementation (Figure 5H and 5I). Taken together, our data suggest an important role of 399 
zinc transporter ZIP13 and ZIP14 in hVIC calcification and osteogenic differentiation. 400 
 401 
3.6 GPR39 expression is decreased in calcified human aortic valves 402 
To better understand the role of GPR39 in CAVD, expression of GPR39 was assessed in 403 
4 non-calcified and 4 calcified human aortic valves. Clinical characteristics of these patients 404 
are shown in Supplementary material Table II. Calcium deposition in human aortic valves was 405 
confirmed by positive staining of alizarin red (Figure 6A). Immunohistochemistry showed 406 
that GPR39 expression was dramatically decreased in calcified aortic valves compared to 407 
non-calcified aortic valves (Figure 6A). This observation was further confirmed by a western 408 
blotting analysis of 4 non-calcified aortic valves and 4 calcified aortic valves, which showed a 409 
significant reduction of GPR39 expression in calcified human aortic valves (30% decrease, 410 
p<0.05; Figure 6B). These data are the first to show that GPR39 expression is decreased in 411 
calcified human aortic valves. Furthermore, zinc serum levels were also significantly 412 
decreased in patients with CAVD compared to healthy volunteers (p<0.01; Figure 6C). These 413 
patients had aortic valve sclerosis, which is an early stage of CAVD and characterized by 414 
thickening and calcification of the aortic valve without obstruction of ventricular outflow 415 
(Supplementary Figure I and Supplementary material Table III). There was no significant 416 
difference in age and sex between healthy volunteers and CAVD patients. Body Mass Index 417 
(BMI) was significantly decreased in CAVD patients compared to healthy volunteers (p<0.05, 418 
Supplementary material Table III). A forward stepwise multivariate logistic analysis 419 
(likelihood ratio) including zinc and BMI was performed. Increasing zinc serum levels was 420 
shown to be a significant protective factor of CAVD after adjusted the BMI (OR=0.135; C.I.: 421 
0.022~0.815; P=0.029). The statistical analysis are provided as Supplementary Methods. 422 
 423 
3.7 Reduction of GPR39 in calcified hVICs is blunted by zinc supplementation  424 
In agreement with our previous observations (Figure 6A and B), our in vitro studies 425 
showed that GPR39 expression was also decreased at day 7 in calcified hVICs compared to 426 
non-calcified hVICs, as demonstrated by immunofluorescence staining (p<0.001; Figure 7A) 427 
and western blotting (p<0.01; Figure 7B). Interestingly, zinc supplementation significantly 428 
attenuated the reduction of GPR39 in calcified hVICs (Figure 7A and 7B).  429 
 430 
4. Discussion 431 
 432 
The current study identifies that zinc as a novel inhibitor of CAVD. Zinc 433 
supplementation significantly inhibits hVIC in vitro calcification, and this inhibitory effect is 434 
abolished by the zinc chelator TPEN. Mechanistically, zinc supplementation inhibits 435 
osteogenic differentiation and prevents apoptosis of hVICs, which is at least in part mediated 436 
by GPR39-dependent ERK1/2 signaling pathway. Also, a significant reduction in the zinc 437 
sensing receptor GPR39 expression in human calcified aortic valves is observed, and zinc 438 
serum levels are decreased in patients with CAVD compared to healthy volunteers. 439 




calcification and osteogenic differentiation. This study provides direct evidence to show that 441 
zinc supplementation inhibits the pathological process of CAVD, and highlights an important 442 
role of ZIP13 and ZIP14 in the progression of CAVD.  443 
 444 
Zinc, a vital trace element for normal health, is associated with a number of human 445 
diseases, including cardiovascular disease, and diabetes. To our knowledge, the current study 446 
is the first report indicating that zinc supplementation effectively inhibits hVIC in vitro 447 
calcification. Zinc bioavailability is influenced by many factors in healthy individuals, 448 
including zinc status of individuals, total zinc concentration and availability of soluble zinc in 449 
the diet. The optimal serum zinc concentrations in adults are maintained between 13.8–22.9 450 
μM23. We showed that 20 μM ZnSO4 within this normal range was sufficient to inhibit 451 
calcium deposition in hVICs. In addition, zinc is predominantly carried by serum albumin in 452 
the blood18. Addition of serum albumin did not alter the inhibitory effect of zinc on hVIC in 453 
vitro calcification. Our further analysis using TPEN chelator and ZnCl2 confirmed the specific 454 
inhibitory effect of zinc on calcification. Taken together, these data suggest that zinc is a key 455 
inhibitor of CAVD.  456 
 457 
Previous studies have shown that osteogenic transition of hVICs plays a crucial role in 458 
the pathogenesis of CAVD4, 8. In the present study, zinc treatment significantly inhibited the 459 
osteogenic gene MSX2 and ALPL mRNA expression after 7 days. These data are consistent 460 
with a recent study showing that zinc inhibits high phosphate-induced osteogenic transition of 461 
human VSMCs15. However, zinc has previously been reported to enhance osteogenic 462 
differentiation of human mesenchymal stem cells via up-regulation of RUNX224. The 463 
existence of cell-mediated differences may account for the different osteogenic responses 464 
among these cells following zinc treatment.  465 
 466 
Apoptosis is a key regulator of initiation and progression of CAVD9-11. Apoptotic bodies 467 
expose phosphatidylserine on the outer membranes and generate a potential calcium-binding 468 
site suitable for hydroxyapatite deposition25, 26. We showed that zinc attenuated apoptosis 469 
during hVIC in vitro calcification process, but did not affect calcium phosphate precipitation. 470 
Therefore, zinc-mediated inhibitory effect on hVIC calcification may involve inhibition of 471 
apoptosis. These results also support previous reports demonstrating that zinc 472 
supplementation prevents apoptosis in a number cell types including cardiomyocytes27, 473 
VSMCs28, and in cardiac allografts29. In the present study, we showed that zinc 474 
supplementation significantly attenuated TNFα mRNA expression during hVIC in vitro 475 
calcification. TNFα, a pleiotropic cytokine, regulates a range of cellular activities including 476 
proliferation, differentiation and apoptosis. TNFα-mediated signaling pathways have been 477 
shown to play an important role in cardiovascular calcification30, 31. Furthermore, previous 478 
studies have reported TNFα accelerates the calcification of hVICs through the BMP2-Dlx5 479 
pathway32. Future studies are required to address whether the inhibitory effect of zinc on 480 
hVIC calcification is mediated through down-regulation of TNFα or the reduced expression of 481 
TNFα is just a consequence of cellular remodeling in calcification. 482 
 483 




revealed that ZIP13 and ZIP14 were the most up-regulated ZIP family members in hVICs 485 
following zinc treatment. ZIP13 is localized in intracellular vesicles and releases zinc from 486 
vesicular stores33. We showed that knockdown of ZIP13 attenuated hVIC in vitro calcification, 487 
and this inhibitory effect was further increased in the presence of zinc treatment. These results 488 
suggest a zinc storage in intracellular vesicles plays a key role in hVIC in vitro calcification. 489 
Interestingly, it has been reported that Zip13 knockout mice show reduced osteogenesis and 490 
abnormal cartilage development, which is mediated at least in part through TGF-β/bone 491 
morphogenetic protein (BMP) signaling pathways33. In addition, ZIP13 has been shown to 492 
suppress beige adipocyte biogenesis and energy expenditure by regulating c/ebp-beta 493 
expression34. Consistent with this, knockdown of ZIP13 reduced osteogenic gene MSX2 and 494 
ALPL mRNA expression in hVICs. ZIP14 is responsible for zinc uptake by cells35, and has 495 
been reported to be a critical regulator of glucose homeostasis and beta-cell function35, 36. We 496 
found that knockdown of ZIP14 in hVICs attenuated calcium deposition. However, this 497 
inhibitory effect was abolished by zinc supplementation. This is likely due to a compensatory 498 
role of other zinc transporters in uptake of zinc into cytoplasm from extracellular space when 499 
additional zinc supplementation exists. Additionally, knockdown of ZIP14 decreased   500 
MSX2 mRNA expression in hVICs, suggesting ZIP14-mediated zinc uptake may regulate 501 
osteogenic differentiation of hVICs. Taken together, our data expand upon these findings and 502 
highlight the important role of ZIP13 and ZIP14 in the maintenance of intracellular zinc 503 
homeostasis in hVIC in vitro calcification and their potential roles in CAVD. The mechanisms 504 
underlying the anti-calcific effects of ZIP13 or ZIP14 silencing are currently elusive and 505 
require further study. 506 
 507 
It should be noted that extracellular zinc and intracellular zinc have opposite role in the 508 
regulation of hVIC calcification and osteogenic differentiation. Extracellular zinc may signal 509 
through GPR39 to activate a number of intracellular signaling pathways21, thereby regulating 510 
hVIC calcification and osteogenic differentiation. However, intracellular zinc mediated by 511 
zinc transporters may act as co-factors for a number of enzymes such as ALPL37, which play 512 
an important role in hVIC calcification and osteogenic differentiation. 513 
 514 
In order to characterize the underlying mechanisms through which zinc exerts its 515 
protective on hVICs, the PI3-kinase/AKT and MAPK/ERK1/2 signaling pathways were 516 
investigated. These pathways play an important role in a wide range of cellular functions, 517 
including cell proliferation, cell survival, and calcification38, 39. We showed that zinc treatment 518 
only induced the phosphorylation of ERK1/2 in hVICs, which is consistent with previous 519 
reports showing that activation of this pathway by zinc in skeletal muscle cells40, myogenic 520 
cells41, and colonocytes42. In contrast to these studies, no induction of AKT phosphorylation 521 
by zinc was observed in hVICs. We also demonstrated that either pharmacological or 522 
siRNA-mediated inhibition of ERK1/2 signaling pathway significantly blunted the protective 523 
effect of zinc on hVIC in vitro calcification and apoptosis. Indeed, the ERK1/2 signaling 524 
pathway has been shown to regulate calcification in osteoblasts43, VSMCs44, and human 525 
VICs45. However, some previous studies have reported that the activation of ERK1/2 526 
signaling pathway exerts pro-calcific effects in valvular calcification. The disparate findings 527 




high calcium and phosphate vs. fibrin and tissue culture polystyrene) and species (human vs. 529 
porcine)19. In addition, inhibition of ERK1/2 signaling pathway has been shown to attenuate 530 
aortic valve disease processes in an Emilin1-deficient mouse model46. The abnormalities of 531 
aortic valves in these mice include early elastic fiber fragmentation and aberrant angiogenesis, 532 
however no aortic valve calcification was detected at any stage46, 47. Further investigations are 533 
required to examine the effects of zinc-mediated ERK1/2 signaling pathway on aortic valve 534 
calcification using mouse models of CAVD. Taken together, our data confirms and extends 535 
these previous reports indicating the importance of the ERK1/2 signaling pathway in the 536 
regulation of CAVD.  537 
 538 
GPR39 has been functionally characterized as a zinc-dependent, G-protein coupled 539 
receptor that senses changes in extracellular zinc and mediates zinc dependent cellular 540 
signaling pathways48. It is widely expressed by a number of cell types including vascular 541 
endothelial cells and VSMCs15, 21. We extended on these previous studies showing that 542 
GPR39 is expressed by hVICs, and silencing of GPR39 abrogated zinc activation of ERK1/2 543 
signaling pathway. We also showed that inhibition of ERK signaling pathway attenuated 544 
zinc-mediated inhibitory effect on hVIC apoptosis and calcification. In addition, knockdown 545 
of GPR39 blunted the inhibitory effect of zinc supplementation on hVIC in vitro calcification, 546 
osteogenic differentiation and apoptosis. Taken together, these data support that zinc signals 547 
through GPR39 to activate ERK1/2 signaling pathway, thereby suppressing osteogenic 548 
differentiation and apoptosis, which could inhibit hVIC calcification. 549 
 550 
The most important observation in this study was that the zinc sensing receptor GPR39 551 
expression was decreased in calcified hVICs and human aortic valves from patients with 552 
CAVD. The pathological role of GPR39 deficiency has been previously described. Deletion of 553 
GPR39 in mice results in zinc deficiency symptoms including depression, accelerated gastric 554 
emptying, and increased fecal excretion49. Furthermore, GPR39 knockout mice display 555 
enhanced high fat-induced obesity due to altered adipocyte metabolism50. Interestingly, we 556 
observed that zinc treatment prevented the reduction of GPR39 in calcified hVICs. This is in 557 
consistent with a previous report showing that zinc deficiency reduces expression of the 558 
GPR39 receptor in the mouse frontal cortex51. These data raise the possibility that zinc 559 
supplementation may reverse aortic valve calcification. It would be interesting to investigate 560 
whether zinc supplementation could reverse the established aortic valve calcification in mouse 561 
models of CAVD. Nonetheless, our data provide novel evidence that support a key role of 562 
GPR39 deficiency in the pathogenesis of CAVD.  563 
 564 
Reduced zinc levels are commonly seen in patients with chronic kidney disease (CKD)52. 565 
In addition, reduced zinc serum levels are also associated with carotid artery atherosclerosis in 566 
hemodialysis patients53. Interestingly, a recent study has shown that zinc serum concentrations 567 
inversely correlated with serum calcification propensity in CKD patients15. In accordance 568 
with these studies, we observed a significant reduction in zinc serum levels in a cohort of 569 
Chinese CAVD patients compared to healthy volunteers. These data together with our hVIC in 570 
vitro calcification studies highlight the important inhibitory role of zinc in the development of 571 




It should be noted that this study may contain some limitations. The hVICs used in the 573 
present study were isolated from diseased aortic valve tissues, which may be more sensitive to 574 
apoptosis and cell death. In addition, the inhibitory or reversal effect of zinc on CAVD was 575 
not tested in vivo. Future studies are required to investigate whether zinc supplementation can 576 
inhibit or reverse aortic valve calcification using mouse models of CAVD. 577 
  578 
In conclusion, we report that zinc as a novel inhibitor of CAVD. The zinc sensing 579 
receptor GPR39 is reduced in calcified aortic valves from patients with CAVD. The 580 
anti-calcific effect of zinc on hVIC calcification is at least in part mediated through inhibition 581 
of apoptosis and osteogenic differentiation via GPR39 dependent EKR1/2 signaling pathway. 582 
Our study also highlights an important role of zinc transporter ZIP13 and ZIP14 in CAVD. 583 
This work warrants further investigations of zinc supplementation or zinc transporter ZIP13 584 
and ZIP14 as a potential novel therapeutic strategy for treatment of CAVD.  585 
 586 
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Figure legends 793 
 794 
Figure 1. Zinc inhibits hVICs in vitro calcification and osteogenic differentiation. hVICs 795 
were exposed to control (Ctr), calcification media (Cal), ZnSO4 with or without TPEN, ZnCl2 , 796 
and ZnSO4 with or without albumin for up to 7 days as indicated. A. Representative alizarin 797 
red S staining images at day 7 (n=3). Plate view (upper) and microscopic view (lower), scale 798 
bar 100 μm. B. Quantitative calcium assay showed that ZnSO4 inhibited hVIC in vitro 799 
calcification at day 7 (n=4). C. Representative confocal images of FluoZin-3 staining at day 3 800 
and day 7 (n=3). Scale bar 50 μm. D. Quantitative calcium assay showed that 10 μM TPEN 801 
blunted the inhibitory effect of ZnSO4 on hVIC in vitro calcification at day 7 (n=4). E. 802 
Quantitative calcium assay at day 7 (n=4). F and G. Quantitative RT-PCR for MSX2 and ALPL 803 
mRNA expression in hVICs cultured with calcifying media after 7 days (n=6). H. Quantitative 804 
calcium assay showed that albumin did not affect the inhibitory effect of ZnSO4 on hVIC in 805 
vitro calcification (n=4). Results are presented as mean ± SEM. ANOVA by Bonferroni 806 
post-test, *p < 0.05, ***p < 0.001 compared to control, #p<0.05, ##p<0.01, ###p < 0.001 807 
compared to calcification. +++p < 0.001 compared to calcification with zinc treatment.  808 
 809 
Figure 2. Zinc prevents apoptosis of hVICs under calcifying conditions. hVICs were 810 
exposed to control (Ctr) or calcification media (Cal) with or without 20 μM of ZnSO4 811 
treatment. A. Cell death at day 3 and day 7 (n=6). B. Representative apoptotic nuclei images 812 
of DAPI staining (left panel) and quantitative analysis of the percentage of apoptotic cells 813 
(right panel). White arrows indicate apoptotic cells, scale bar 10 μm (n=11). C. Flow 814 
cytometry analysis of Annexin V and Propidium Iodide (PI) staining (upper panels) and 815 
quantification of the percentage of early apoptotic cells (Q3, lower panel) at day 3 (n=3). D. 816 
Representative western blot of Caspase 3, cleaved Caspase 3, and β-actin (n=4). E. Calcium 817 
phosphate precipitation analysis showed that ZnSO4 did not affect calcium/phosphate 818 
deposition (n=4). F. Quantitative RT-PCR for TNFα mRNA expression in hVICs cultured with 819 
calcifying media after 7 days (n=6). G. Quantitative RT-PCR for TGFβ mRNA expression 820 
(n=5 or 6). Results are presented as mean ± SEM. ANOVA by Bonferroni post-test. *p < 0.05, 821 
**p < 0.01, ***p < 0.001 compared to control. #p < 0.05, ##p < 0.01, ###p < 0.001 compared to 822 
calcification. 823 
 824 
Figure 3. Zinc inhibits hVICs calcification and apoptosis through activation of the 825 
ERK1/2 signaling pathway. hVICs were exposed to control (Ctr), calcification media (Cal), 826 
20 μM ZnSO4 treatment with or without 10 μM ERK inhibitor (PD98059) or siERK1/2 as 827 
indicated. A. hVICs were exposed to ZnSO4 for 10, 30, and 60 minutes. Representative 828 
western blot of phospho-AKT (p-AKT), total AKT, phospho-ERK (p-ERK), total ERK, and 829 
β-actin (left panel) and quantification of the relative protein expression (right panel) (n=4). B. 830 
Representative alizarin red S staining images at day 7 (n=3). Plate view (upper) and 831 
microscopic view (lower), scale bar 100 μm. C. Quantitative calcium assay at day 7 (n=4). D. 832 
Representative Western blot of Caspase 3, cleaved Caspase 3, and β-actin (n=4). E. Cell death 833 
at day 7 (n=6). F. Quantitative calcium assay at Day7 (n=4). Results are presented as mean ± 834 
SEM. ANOVA by Bonferroni post-test. *p < 0.05, **p < 0.01, ***p < 0.001 compared to 835 




calcification with zinc treatment.  837 
 838 
Figure 4. Zinc signals through the zinc-sensing receptor GRR39 to inhibit hVICs 839 
calcification. hVICs were transfected with GPR39 siRNA (siGPR39) or negative control 840 
siRNA (siNC) and exposed to control (Ctr), calcification media (Cal) with or without 20 μM 841 
of ZnSO4 treatment. A. Representative western blot of GPR39 from 5 independent hVICs 842 
isolation. B. GPR39 silencing efficiency using three different siRNA (n=3). GPR39 siRNA 2 843 
was selected for subsequent experiments. C. Representative western blot of phospho-AKT 844 
(p-AKT), total AKT, phospho-ERK (p-ERK), total ERK, and β-actin after 30 minutes with 845 
ZnSO4 (n=4). D. Representative alizarin red S staining images at day 7 (n=3). Plate view 846 
(upper) and microscopic view (lower), scale bar 100 μm. E. Quantitative analysis of calcium 847 
content at day 7 (n=5). F. Representative western blot of Caspase 3, cleaved Caspase 3, and 848 
β-actin (n=4). G-I. Relative mRNA expression of MSX2, BMP2 and RUNX2 (n=6). Results 849 
are presented as mean ± SEM. ANOVA by Bonferroni post-test. *p < 0.05, **p < 0.01, ***p < 850 
0.001 compared to control plus siNC. #p < 0.05, ##p < 0.01, ###p < 0.001 compared to 851 
calcification plus siNC. +p < 0.05, +++p < 0.001 compared to calcification with zinc treatment 852 
plus siNC. 853 
 854 
Figure 5. Knockdown of ZIP13 or ZIP14 inhibits hVIC in vitro calcification and 855 
osteogenic differentiation. hVICs were exposed to control (Ctr), or 20 μM ZnSO4 treatment 856 
for 2 days, or transfected with siZIP13 or siZIP14, and exposed to calcification media (Cal) or 857 
20 μM ZnSO4 treatment for up to 7 days as indicated. A. Relative mRNA expression of zinc 858 
transporter ZIP1-14 was examined by quantitative RT-PCR (n=6 or 8), unpaired Student’s 859 
t-test. B. Representative alizarin red S staining images for hVICs transfected with siZIP13 at 860 
day 7 (n=3). C. Quantitative analysis of calcium content for hVICs transfected with siZIP13 at 861 
day 7 (n=5), ANOVA by Bonferroni post-test. D. Representative alizarin red S staining 862 
images for hVICs transfected with siZIP14 at day 7 (n=3). E. Quantitative analysis of calcium 863 
content for hVICs transfected with siZIP14 at day 7 (n=5), ANOVA by Bonferroni post-test. 864 
F-G. Relative mRNA expression of MSX2 and BMP2 at Day 7 (n=8). ANOVA by Bonferroni 865 
post-test. H-I. Representative confocal images of FluoZin-3 staining at day 7 and quantitative 866 
analysis of zinc fluorescence intensity (n=6), ANOVA by Bonferroni post-test. Scale bar 50 867 
μm. Results are presented as mean ± SEM. *p<0.05, **<0.01, ***p < 0.001 compared to 868 
control. #p < 0.05, ### p< 0.001 compared to calcification plus siNC. +p<0.05, ++p < 0.01, +++p 869 
< 0.001 compared to calcification with zinc treatment plus siNC. 870 
 871 
Figure 6. GPR39 expression is down-regulated in calcified human aortic valves. A. 872 
Immunohistologic evaluation of GPR39 expression in non-calcified and calcified human 873 
aortic valves (n=3). B. Representative western blot of GPR39 expression from 4 non-calcified 874 
or calcified human aortic valves (upper panels) and relative GPR39 expression (lower panel) 875 
(n=4), unpaired Student’s t-test. C. Serum zinc concentrations in healthy and CAVD patients 876 
(n=15), Mann-Whitney test. Results are presented as mean ± SEM. *p < 0.05, **p < 0.01 877 
compared to control. 878 
 879 




calcification in vitro. hVICs were exposed to control (Ctr) or calcification media (Cal) with 881 
or without additional 20 μM of ZnSO4 at day 3 and day 7. A. Representative confocal images 882 
of GPR39 immunostaining and relative GPR39 fluorescence intensity (lower panel) (n=8), 883 
ANOVA by Bonferroni post-test. B. Western blot of GPR39 expression (upper panel) and 884 
relative GPR39 expression (lower panel) (n=4), ANOVA by Bonferroni post-test. Results are 885 
presented as mean ± SEM. *p < 0.05, **p < 0.01, **p < 0.001 compared to control. #p < 0.05, 886 
##p < 0.01 compared to calcification. 887 
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Supplementary Figure I. A representative still image of echocardiograms of a patient
with CAVD.
Supplementary Figure I
Supplementary Figure II. Validation of hVICs in vitro calcification model. hVICs were 
exposed to control (Ctr) or calcification media (Cal) for up to 7 days. A. Representative 
confocal images of vimentin and alpha 22-smooth muscle actin (Sm22-α) 
immunofluorescence staining (left panel) and quantitative analysis of percentage of cells 
expressing double valve interstitial cell markers (vimentin and Sm22-α) or single marker 
(right panel) (n=6). Scale bar 20 µm. B. Representative alizarin red S staining images at 
day 7 (n=3). Plate view (upper) and microscopic view (lower), scale bar 100 µm. C. 
Quantitative calcium assay at day 7 (n=4). D. Relative mRNA expression of ALPL, MSX2, 
and RUNX2 at day 2 (n=12), unpaired Student’s t-test or Mann-Whitney test. E. Cell death 
at day 3 and day 7 (n=6). F. Flow cytometry analysis of Annexin V and Propidium Iodide 
(PI) staining (left panels) and quantification of the percentage of early apoptotic cells (Q3, 
right panel) at day 3 (n=3), unpaired Student’s t-test. Results are presented as mean ± 
SEM.*p < 0.05, **p < 0.01, ***p < 0.001 compared to control.
Supplementary Figure III. Zinc does not alter calcium deposition on fixed hVICs. hVICs were
fixed with 4% PFA and then exposed to control (Ctr) or calcification media (Cal) without or with 20
µM of ZnSO4 treatment for 7 days. A. alizarin red staining. B, calcium quantitative assay (n=4).
Results are presented as mean ± SEM. ANOVA by Bonferroni’s test. ***p < 0.001 compared to
control.
Supplementary Figure IV. ERK1/2 inhibitor PD98058 did not alter hVIC in vitro
calcification. hVICs were exposed to control (Ctr) or calcification media (Cal) without or
with 10 µM PD98059 for up to 7 days. A. Representative alizarin red S staining images
at day 7 (n=3). B. Quantitative calcium assay at Day 7 (n=5).Results are presented as
mean± SEM. ANOVA by Bonferroni’s test. ***p < 0.001 compared to control.
Supplementary Figure V. Knockdown efficiency of siERK1/2, siZIP13 and siZIP14.
hVICs were transfected with siNC, siER1/2, siZIP13 or siZIP14 as indicated. A. Relative
mRNA expression of ERK1 (MAPK3) and ERK2 (MAPK1) (n=6), ANOVA by Bonferroni
post-test. B. Western blotting images for ERK1/2 expression (n=4). C. Semi-quantitative
analysis of expression of ERK1/2 (n=4), unpaired Student’s t-test. D. Relative mRNA
expression of ZIP13 (n=6), ANOVA by Bonferroni post-test. E. Western blotting images for
ZIP13 expression (n=4). F. Semi-quantitative analysis of expression of ZIP13 (n=4),
unpaired Student’s t-test. G. Relative mRNA expression of ZIP14 (n=6), ANOVA by
Bonferroni post-test. H. Western blotting images for ZIP14 expression (n=4). I. Semi-
quantitative analysis of expression of ZIP14 (n=4), unpaired Student’s t-test. Results are
presented as mean ± SEM. ANOVA by Bonferroni’s test. *p<0.05, **p<0.01, ***p < 0.001
compared to siNC.
Supplementary Figure VI. ZIP13 and ZIP14 protein expression in human non-calcified
and calcified aortic valves. A. Western blotting images for ZIP13 and ZIP14 expression
(n=4). B. Semi-quantitative analysis of expression of ZIP13 and ZIP14 (n=4), unpaired
Student’s t-test. Results are presented as mean± SEM.
Supplementary Table I. Clinical Characteristics of CAVD Patients for the
isolation of hVICs.
CAVD indicates calcific aortic valve disease; BMI, body mass index; LDL, low-density
lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; ACEI/ARB,







Diabetes mellitus, % 3
















Age, years 56±3.58 65±3.09 0.098
Male, % 100 100 1
Smoking, % 0 25 1
Hypertension, % 100 0 0.0286
Diabetes mellitus, % 0 0 1
Bicuspid aortic valves, % 0 0 1
BMI, kg/m2 23.19±1.2 24.63±1.88 0.5416
Triglycerides, mmol/L 1.27±0.32 1.05±0.08 0.5011
LDL, mmol/L 2.84±0.30 2.88±0.43 0.9495
HDL, mmol/L 0.84±0.13 1.23±0.18 0.1527
Cholesterol, µmol/L 4.40±0.34 4.66±0.54 0.693
Statins, % 25 0 1
Beta-blocker, % 75 50 1
ACEI/ARB, % 75 0 0.1429
Supplementary Table II. Clinical Characteristics of Patients for the aortic valves studies. 
CAVD indicates calcific aortic valve disease; BMI, body mass index; LDL, low-density
lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; ACEI/ARB, Angiotensin
Converting Enzyme Inhibitors/ Angiotensin Receptor Blockers. Values are mean±SEM
when appropriate. P values determined by the Student t test or Fisher exact test.
Supplementary Table III. Clinical Characteristics of Patients for the Zinc Serum Level.
CAVD indicates calcific aortic valve disease; BMI, body mass index; LDL, low-
density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol;
ACEI/ARB, Angiotensin Converting Enzyme Inhibitors/ Angiotensin Receptor
Blockers; LVEF, left ventricular ejection fraction; AV, Aortic valve orifice velocity;
AOD, Aortic diameter; Values are mean±SEM when appropriate. P values








Age, years 69.47±1.34 73.4±1.64 0.0737
Male, % 53 100 0.2451
Smoking, % NA 86 NA
Hypertension, % NA 60 NA
Diabetes mellitus, % NA 27 NA
Bicuspid aortic valves, % NA 7 NA
BMI, kg/m2 23.97±0.5 21.69±0.7 0.0131
Triglycerides, mmol/L NA 1.33±0.16 NA
LDL, mmol/L NA 2.92±0.20 NA
HDL, mmol/L NA 1.26±0.34 NA
Cholesterol, μmol/L NA 4.58±0.23 NA
Statins, % NA 73 NA
Beta-blocker, % NA 67 NA
Marked increase in 
echogenicity of aortic valves
0 15 <0.0001
LVEF, % 57.73±3.37 54.95±3.81 0.5903
AV, m/s 1.173±0.07 1.486±0.11 0.0186
AOD, cm 2.94±0.07 2.97±0.09 0.8076
1 
Supplementary Table IV




Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title 
or the abstract 
1 
(b) Provide in the abstract an informative and balanced summary of
what was done and what was found
1 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation 
being reported 
2-3
Objectives 3 State specific objectives, including any prespecified hypotheses 2-3
Methods 
Study design 4 Present key elements of study design early in the paper 3 
Setting 5 Describe the setting, locations, and relevant dates, including periods 
of recruitment, exposure, follow-up, and data collection 
3 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of case
ascertainment and control selection. Give the rationale for the choice 
of cases and controls 
3 
(b) For matched studies, give matching criteria and the number of
controls per case
N/A 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 







8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group 
3 
Bias 9 Describe any efforts to address potential sources of bias 3 
Study size 10 Explain how the study size was arrived at 3,10 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the analyses. If 









(b) Describe any methods used to examine subgroups and interactions N/A 
(c) Explain how missing data were addressed 3,10, 
Supplementary 
Methods 
(d) If applicable, explain how matching of cases and controls was
addressed
3,10 
(e) Describe any sensitivity analyses N/A 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and analysed 
3 
(b) Give reasons for non-participation at each stage 3 




*Give information separately for cases and controls. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at http://www.strobe-statement.org. 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, 













Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 











(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
N/A 





Key results 18 Summarise key results with reference to study objectives 10-14 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias 
or imprecision. Discuss both direction and magnitude of any potential bias 
13-14 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
10-14 
Generalisability 21 Discuss the generalisability (external validity) of the study results 10-14 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is based 
14 
Supplementary Table V. The qPCR primer sequences for target genes 























TGFβ1 CAATTCCTGGCGATACCTCAG GCACAACTCCGGTGACATCAA 
siRNA Sequence (5ʹ-3ʹ)
GPR39 siRNA 1 AGUGACUGCUCCCAAAUCA
GPR39 siRNA 2 GACAGACCACAUGGUGAGU
GPR39 siRNA 3 AUGCCCAUGGAGUUCUACA
MAPK1 siRNA 1 GAACATCATTGGAATCAAT
MAPK1 siRNA 2 GCTACACCAACCTCTCGTA
MAPK1 siRNA 3 GCACCAACCATCGAGCAAA
MAPK3 siRNA 1 CCTCCAACCTGCTCATCAA
MAPK3 siRNA 2 GACCGGATGTTAACCTTTA
MAPK3 siRNA 3 GCTACACGCAGTTGCAGTA
ZIP13 siRNA 1 GCTTCCTTGTGAGCAAGAA
ZIP13 siRNA 2 CTGACCTCTTGGAAGAAGA




Supplementary Table VI. siRNA sequences for gene silencing
Supplementary Methods 
All statistical testing was 2-sided, with P < 0.05 considered significant. Analyses 
were performed using IBM SPSS Statistics 19.0 (IBM Corporation, Chicago, USA). 
The comparison of the baseline variables of interest were performed according to the 
patients with CAVD or not. Continuous variables, such as age, Zn and BMI, were 
denoted as mean ± standard deviation, and student’s t test was conducted to compare 
the variables. Category variables, such as sex, were denoted as number (proportions) 
of female, and χ2 test was conducted to compare the variables. Table 1showed that 
there is a significant lower Zn concentration (17.1±0.6 vs 17.9 ± 0.8 μmol/L, 
P=0.014) and lower BMI (21.7 ± 2.7 vs 23.9 ± 1.9 kg/m2, P=0.013) in CAVD group. 
There is no significant difference of sex and age between the two groups.  
Table 1 baseline characteristics of different groups 
 
Table 2 showed the univariate and multivariate analyses of the variables 
predicting CAVD. The increasing Zn and BMI showed to be a significant protect 
factor of CAVD from the univariate analyses. After adjusting all the 4 variables of 
baseline, only the increasing BMI is the independent protective factor with a 
statistical significance (OR=0.598; C.I.: 0.371~0.966; P=0.035). There is an apparent 







Age, Mean (SD), y 73.4 (6.4) 69.5 (5.2) 0.074 
Female, No. (%) 3 (20) 7 (47) 0.13 
Zn, mean (SD), μmol/L 17.1 (0.6) 17.9 (0.8) 0.014 
BMI, mean (SD), kg/m2 21.7(2.7) 23.9 (1.9) 0.013 
(OR=0.128; C.I.: 0.015~1.090; P=0.060). We believe that this negative result attribute 
to the small participates number. 
 
Table 2 univariable and multivariable analysis 
 Univariable analysis Multivariable analysis 
 OR 95% C.I. P OR 95% C.I. P 
Age increase 1  1.132 [0.983~1.303] 0.084 1.111 [0.896~1.378] 0.339 
Male  3.500 [0.692~17.714] 0.130 3.740 [0.394~35.482] 0.251 
Zn increase 1 0.148 [0.026~0.826] 0.029 0.128 [0.015~1.090] 0.060 
BMI increase 1 0.653 [0.449~0.950] 0.026 0.598 [0.371~0.966] 0.035 
 
Furthermore, considering that there is no difference in the baseline and univariate 
analysis in age and sex and only 15 patients were diagnosed with CAVD, it is rational 
to include no more than 2 variables in the final multivariate analyses according to the 
statistical rule: the events per variable should be 10 or more. We performed a forward 
stepwise multivariate logistic analysis (likelihood ratio) to get a more convincible 
result. Only Zn and BMI were included in the final model (Table 3). From this result, 
increasing Zn was proved to be a significant protective factor of CAVD after adjusted 
the BMI (OR=0.135; C.I.: 0.022~0.815; P=0.029). 
 
Table 3 univariable and multivariable analysis of forward stepwise logistic analysis 
 Univariable analysis Multivariable analysis 
 OR 95% C.I. P OR 95% C.I. P 
Age increase 1  1.132 [0.983~1.303] 0.084    
Male  3.500 [0.692~17.714] 0.130    
Zn increase 1 0.148 [0.026~0.826] 0.029 0.135 [0.022~0.815] 0.029 
BMI increase 1 0.653 [0.449~0.950] 0.026 0.603 [0.377~0.966] 0.035 
 







